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Background: The objective of this study was to evaluate fluid-bed coating as a new technique 
to prepare a pellet-based solid self-nanoemulsifying drug delivery system (SNEDDS) using 
cyclosporin A as a model of a poorly water-soluble drug.
Methods: The rationale of this technique was to entrap a Liquid SNEDDS in the matrix of 
the coating material, polyvinylpyrrolidone K30, by fluid-bed coating. Pseudoternary phase 
diagrams were used to screen the liquid SNEDDS formulations. The optimal formulation was 
composed of Labrafil M® 1944 CS, Transcutol P®, and Cremophor® EL in a ratio of 9:14:7. To 
prepare solid SNEDDS pellets, liquid SNEDDS was first dispersed in an aqueous solution of 
polyvinylpyrrolidone and then sprayed onto the surface of non-pareil pellets. Upon evaporation 
of water, polyvinylpyrrolidone precipitated and formed tight films to entrap the liquid SNEDDS. 
Visual observation and scanning electron microscopic analysis confirmed good appearance of 
the solid SNEDDS pellets.
Results: Our results indicated that up to 40% of the liquid SNEDDS could be entrapped in 
the coating layer. Powder x-ray diffraction analysis confirmed nonexistence of crystalline 
cyclosporin A in the formulation. Solid SNEDDS pellets showed a slower redispersion rate than 
the liquid SNEDDS. An increase in the total liquid SNEDDS loading led to faster redispersion, 
whereas increased coating weight (up to 400%) significantly decreased the redispersion rate. 
Both cyclosporin A loading and protective coating with 5% polyvinylpyrrolidone K30 did not 
significantly affect the redispersion rate.
Conclusion: It is concluded that fluid-bed coating is a new technique with considerable potential 
for preparation of pellet-based solid SNEDDS formulations.
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Introduction
A large number of marketed drugs or drug candidates are poorly water-soluble, which 
results in poor oral absorption, high intrasubject and intersubject variability, and lack 
of dose proportionality.1 In order to overcome these problems, different approaches, 
including solid dispersion, inclusion complexation, cosolubilization, and micronization, 
have been employed.2 Recently, much attention has been paid to lipid-based formu-
lations, especially self-emulsifying and self-nanoemulsifying drug delivery systems 
(SNEDDSs).3 In general, SNEDDS is an isotropic mixture of drug, oil, surfactants, and 
cosurfactants, which forms an oil-in-water nanoemulsion upon contact with aqueous 
medium under gentle agitation.4–6 SNEDDSs are commonly formulated in a liquid 
state and further encapsulated into soft gelatin capsules before use. However, the soft 
capsule formulations have some disadvantages, including low drug compatibility, poor International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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stability, drug leakage and precipitation, capsule aging, and 
high production costs. Therefore, it is desirable to formulate 
SNEDDSs into solid dosage forms.
One of the initial concepts of a solid SNEDDS was 
proposed by Nazzal et al when they were formulating a 
eutectic liquid7,8 into a tablet using blends of maltodextrin, 
modified povidone, and microcrystalline cellulose,9,10 which 
was termed “liquisolid” or solid-lipid compact. From then 
on, a number of techniques have been employed to prepare 
solid SNEDDSs. A common strategy is to formulate a liq-
uid SNEDDS into granules using porous adsorbents and 
subsequently compress these into tablets.11–15 Spray-drying 
has also been employed to formulate liquid SNEDDSs into 
free-flowing powders, using adsorbents such as Aerosil 20016 
and dextran.17 Homar et al18 and Zvonar et al6 reported micro-
encapsulation of liquid SNEDDSs to obtain solid powders 
of microcapsules. The powders containing liquid SNEDDS 
can be further formulated into solid dosage forms, such as 
tablets, capsules, and granules. In recent years, there has been 
growing interest in multiple-unit pellet formulations, which 
have appealing properties, including independence of gastric 
transit, flexibility in dose dividing, reduction of intrasubject 
and intersubject variability, and improvement in efficacy and 
safety. SNEDDS pellets have been developed and evaluated 
both in vitro and in vivo in order to enhance the solubility 
and bioavailability of poorly water-soluble drugs.19–23 Up until 
now, melt extrusion/spheronization has been employed as the 
only technique to prepare SNEDDS pellets. The formulation 
process depends highly on liquid SNEDDSs as moistening 
agents or adhesives to prepare paste for extrusion, which 
makes formulation development less flexible.
In our previous studies,24–26 we developed a fluid-bed 
coating technique to prepare solid dosage forms, such as 
solid dispersion and cyclodextrin inclusion complexes, 
from liquids. This technique is based on removal of the 
solvent from the bulk liquid, while the solid precipitates and 
deposits on the surface of non-pareil cores   simultaneously. 
The coating process is highly efficient and can be easily 
scaled up. In this study, we employed this fluid-bed coat-
ing technique to prepare a solid SNEDDS. To avoid use 
of an organic solvent, the liquid SNEDDS was directly 
dispersed in water and spray-dried to achieve coating, 
using polyvinylpyrrolidone K30 as a film-forming mate-
rial in a fluid-bed coater. The most important issues with 
this technique, including the capacity of the coating layer 
to “hold” a liquid SNEDDS, and the redispersibility and 
physicochemical properties of solid SNEDDS pellets, were 
investigated.
Materials and methods
Materials
Cyclosporin A was purchased from the Pharmaceutical 
Factory at the Sichuan Institute of Antibiotic Industries 
(Chengdu, China). Oleoyl macrogolglycerides (Labrafil M® 
1944 CS), caprylocaproyl macrogolglycerides (Labrasol®), 
and diethylene glycol monoethyl ether (Transcutol P®) were 
purchased from Gattefossé Corporation (Brittany, France). 
Ethoxylated castor oil (Cremophor® EL) and polyethylene 
glycol (PEG)-40 hydrogenated castor oil (Cremophor RH 
40) were obtained from BASF Corporation   (Ludwigshafen, 
Germany). PEG 400 was purchased from Gaonan   Chemicals 
(Shanghai, China). Polyvinylpyrrolidone K30 was kindly 
provided by the China Division, ISP Chemicals Co 
(  Shanghai, China). Non-pareil pellets (Suglets® sugar spheres 
PF101, 710–850 µm in diameter) were provided by NP Pharm 
(Bazainville, France). High-pressure liquid chromatographic 
grade methanol, acetonitrile, and tert-butylmethylether were 
provided by Tedia (Carson City, CA). Deionized water was 
prepared using the Millipore purification system (Molsheim, 
France). Other reagents were of analytical grade and used 
as received.
Preparation and characterization  
of liquid sNeDDs
The formulation of the liquid SNEDDS was first screened 
and evaluated before the preparation of the solid SNEDDS. 
Liquid SNEDDS should have the capacity to solubilize 
sufficient drug to avoid possible precipitation during the 
self-nanoemulsifying process. To begin with, the solubility 
of cyclosporin A in oils, surfactants, and cosurfactants was 
investigated. Briefly, excess cyclosporin A was added to each 
of the liquids, after which the mixture was maintained at 25°C 
for 24 hours to reach equilibrium following a previously 
described procedure.27 After centrifugation, the supernatant 
was collected and assayed for cyclosporin A by high-pressure 
liquid chromatography as described below. The highest 
apparent solubility of cyclosporin A was observed in the fol-
lowing order: 1,2-propylene glycol (430 mg/g), Transcutol P 
(340 mg/g), ethyl oleate (125 mg/g), and Labrafil M 1944 
CS (123 mg/g). However, the solubility of cyclosporin A in 
surfactants (such as Cremophor RH 40 and Cremophor EL) 
was moderate (about 80 mg/g).
Liquid SNEDDS formulations were screened by 
pseudoternary phase diagrams using Labrafil M 1944 CS and 
ethyl oleate as oils, Cremophor EL and RH40 as surfactants, 
and Transcutol P and 1,2-propylene glycol as cosurfactants, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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due to the relatively high solubility of cyclosporin A in these 
excipients and their good pharmaceutical acceptance. During 
the construction of the ternary phase diagrams, the composi-
tion of oil, surfactant/cosurfactant, and water was fixed as 
the three vertices of the triangle phase diagram.27 Mixtures 
of oil and surfactant/cosurfactant were titrated by deionized 
water at 37°C. The mixtures were vortex-mixed, and then 
observed visually to identify the formation of nanoemulsion 
presenting as clear or translucent liquids. From the region 
of self-  nanoemulsifying (infinite dilution region within the 
nanoemulsion region) in the phase diagram, the ratio of oil to 
  surfactant/cosurfactant could be easily obtained. By comparing 
a series of phase diagrams at different surfactant/  cosurfactant 
ratios (Km), the composition of liquid SNEDDS could be 
roughly selected. Cyclosporin A was dissolved in blank liquid 
SNEDDS, and its self-nanoemulsifying ability was evaluated 
by visual observation and particle size measurement.
The optimal formulation of cyclosporin A-loaded liquid 
SNEDDS was simply prepared by mixing the components 
selected above. Due to the poor solubility of cyclosporin A, it 
was first dissolved in cosurfactant liquid. Oils and surfactants 
were then added, and the solution was gently stirred to form 
a homogenous mixture.
Preparation and characterization  
of solid sNeDDs pellets
Preparation
Solid SNEDDS pellets were prepared in a fluid-bed coater 
(DPL1/3 Multi-processor, Chongqing Jinggong Pharma-
ceutical Machinery Co Ltd, Chongqing, China) according 
to previously described procedures with modifications.24,25 
Briefly, 500 mL of liquid SNEDDS was diluted with 500 mL 
of water under gentle stirring. Subsequently, a defined 
amount of diluted liquid SNEDDS was poured into an aque-
ous solution containing polyvinylpyrrolidone K30 under 
mechanical stirring to achieve a final mixture containing 
10% polyvinylpyrrolidone K30 (w/v) and liquid SNEDDS 
at a series of concentrations less than 10% (w/v). The mix-
ture was then sprayed through a nozzle onto the surface of 
fluidized non-pareil cores in the fluid-bed coater. Operating 
conditions were as follows: inlet air temperature, 45–55°C; 
product temperature, 35°C; blower frequency, 12–26 Hz; 
rotational speed of peristaltic pump, 4–12 rpm; atomizing air 
pressure, 0.15–0.25 mPa; and spray nozzle diameter, 0.5 mm. 
After coating, the pellets were dried in the coating chamber 
at 35°C for an additional 15 minutes. For the protective 
coating, the solid SNEDDS pellets were further coated with 
polyvinylpyrrolidone K30, with a 5% weight gain.
coating recovery and coating weight gain
The coating recovery (CR) was defined as the ratio of the 
weight of the final solid SNEDDS pellet product (WF) to 
the total weight of non-pareil cores, polyvinylpyrrolidone 
K30, and liquid SNEDDS (WT), and was calculated as: 
CR (%) = WF/WT × 100%.
The coating weight gain (CWG) was used to define the 
ratio of the increased weight of solid SNEDDS layer com-
pared with the weight of non-pareil cores (WC), and was 
calculated as: CWG (%) = (WF − WC)/WC × 100%, where WC 
denotes the weight of the original non-pareil cores.
Friability
Friability of the solid SNEDDS pellets was measured by the 
Chinese Pharmacopoeia Appendix method. The pellets were 
weighed and subjected to friability testing in a CJY-300B 
tester (Shanghai Huanghai Pharmaceutical Control Equip-
ment Co Ltd, Shanghai, China) at 25 rpm for 4 minutes. 
The friability was calculated as the percentage of weight 
loss. A limit of 1% for friability tests was suggested by the 
Chinese Pharmacopoeia 2010 edition.
scanning electron microscopy
Both the surface and cross-section morphology of the solid 
SNEDDS pellets were observed by a scanning electron 
microscope (XL30 Series; Philips, Amsterdam, Holland). 
Prior to examination, the samples were fixed on a brass stub 
using double-sided tape and gold-coated in vacuum by a 
sputter coater. The photographs were taken at an excitation 
voltage of 10 kV .
Powder x-ray diffraction
Powder x-ray diffraction of the samples (cyclosporin A, poly-
vinylpyrrolidone K30, physical mixture, and solid SNEDDS 
powder) was evaluated by an X′Pert PRO diffractometer 
(PANalytical, Almelo, Holland) over the 2.5−45° 2θ range 
at a scan rate of 3° per minute, where the tube anode was 
Cu with Ka = 0.154 nm monochromatized with a graphite 
crystal. The pattern was collected at 40 kV of tube voltage 
and 60 mA of tube current in step scan mode (step size 0.02°, 
counting time 1 second per step). In order to exclude inter-
ference of the non-pareil cores with the x-ray diffraction 
analysis, the solid SNEDDS samples were prepared with 
inert polyvinylchloride beads as a substrate and crushed to 
collect the powder. To prepare the physical mixtures, blank 
solid SNEDDS powder containing 40% liquid SNEDDS 
was mixed with cyclosporin A powder to simulate one of 
the solid SNEDDS formulations that contained 40% liquid International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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SNEDDS in the coating layer and 10% cyclosporin A in 
liquid SNEDDS.
Particle size and zeta potential measurement
The particle size and zeta potential of the nanoemulsion 
was measured by Zetasizer Nano® (Malvern Instruments, 
Malvern, UK) equipped with a 4 mW He-Ne laser (633 nm) 
at 25°C. Samples were diluted with ten volumes of deionized 
water prior to the measurement.
reconstitution study
The solid SNEDDS pellets (100 mg) were dispersed with 
10 mL deionized water by vortex mixing (30 seconds), and 
then incubated for 30 minutes at 25°C. The dispersion was 
then observed visually and characterized for particle size.
redispersibility study
The solid SNEDDS pellets should preserve their ability to 
reconstitute into nanoemulsion upon contact with water. In 
this study, the redispersibility of solid SNEDDS pellets was 
evaluated by monitoring cyclosporin A in the redispersing 
medium. Previously, similar “dissolution” studies have been 
performed to characterize SNEDDSs.4,28 However, it would 
be better to use the term “redispersibility study” rather than 
“dissolution study” because those evaluations were based 
on the quantification of total cyclosporin A in reconstituted 
nanoemulsion rather than free cyclosporin A. The redispers-
ibility test was performed in a ZRS-8G dissolution tester 
(Tianda Tianfa Technology Co Ltd, Tianjin, China) according 
to the Chinese Pharmacopoeia Appendix Method I (the basket 
method) with minor modifications. The redispersing medium 
was 500 mL of deionized water thermostatically maintained 
at 37 ± 0.5°C and stirred at a revolution speed of 100 rpm. 
Solid SNEDDS pellets containing 25 mg cyclosporin A 
were first sealed into hard gelatin capsules and immersed 
into 500 mL redispersing medium. Five milliliter aliquot 
samples were withdrawn at time intervals and immediately 
filtered (Millex® AP, Millipore, 0.4 µm). The filtrate (500 µL) 
was diluted with 500 µL methanol, and a 20 µL sample was 
assayed for cyclosporin A by high-pressure liquid chroma-
tography as described below.
Determination of cyclosporin A
Cyclosporin A was determined by high-pressure liquid 
chromatography/ultraviolet light at a detection wave-
length of 226 nm.29 The LC-10ATvp high-pressure liquid 
chromatography system (Shimadzu, Kyoto, Japan) was 
composed of a binary pump, a tunable ultraviolet detector, 
a column heater, and a manual injector. The mobile phase 
was a   mixture of acetonitrile/water/tert-butylmethylether/ 
phosphoric acid (610/340/50/1, v/v/v/v) pumped at a flow 
rate of 1.0 mL/minute. Cyclosporin A was separated by 
a C18 column (Venusil XBP, 5 µm, 4.6 mm × 150 mm; 
Agela, Newark, DE), which was guarded with a refillable 
precolumn (C18, 2.0 mm × 20 mm; Alltech, Nicholasville, 
KY) and a stainless preheating tube with a length of 1000 mm 
and an internal diameter of 0.25 mm. The temperature of 
the C18 column and the preheating tube was maintained at 
70°C. Samples were prepared according to the following 
procedures: for liquid SNEDDS, the samples were directly 
diluted with methanol; for solid SNEDDS, the pellets were 
first ground into fine powder and extracted with methanol; 
and for the redispersibility study, the samples were directly 
diluted with methanol to destroy the nanoemulsion structure 
and release cyclosporin A. The linearity ranged from 1.0 to 
50 µg/mL, with a correlation coefficient of 0.9997 ± 0.0002. 
Intraday and interday precisions were all below 2%.
statistical analysis
All results were expressed as the mean ± standard devia-
tion. Data for the different formulations were compared by 
one-way analysis of variance. P , 0.05 was considered to 
be statistically significant.
Results and discussion
Preparation and characterization of liquid 
sNeDDs
The results of the phase diagram study outline the range of 
oil, surfactant, and cosurfactant combinations that possess 
a good self-nanoemulsifying ability, as shown in a typical 
pseudoternary phase diagram (Figure 1). In the phase dia-
gram, the area of self-nanoemulsifying, which can be 
diluted infinitely without obvious changes in appearance, 
is shown in dark, whereas the nanoemulsion area, which 
transits into a milky emulsion upon dilution with water, is 
shown in gray. From the self-nanoemulsifying areas, the 
ratio of oil/  (surfactant +   cosurfactant) could be easily read. 
By carefully comparing the phase diagrams obtained at 
different Km (surfactant/cosurfactant) values, we estimated 
the self-nanoemulsifying formulation range. The optimal 
formulation was selected according to the criteria of rapid 
self-nanoemulsifying ability, higher solubility of cyclosporin 
A, and less use of surfactants. Table 1 shows six optimal for-
mulations containing different types of oils, surfactants, and 
cosurfactants, which were further evaluated for their ability to 
solubilize cyclosporin A. We found that the highest solubility International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of 170 mg/g and 160 mg/g was from   formulation 4 (F4) and 
formulation 6 (F6), respectively (Table 1).   Figure 1 shows that 
the particle size of F4 was approximately 21 nm, which was 
determined after ten times of dilution by water.   Furthermore, 
up to 10% of cyclosporin A loading did not significantly affect 
particle size (Table 1). However, the particle size was signifi-
cantly increased by up to 12% cyclosporin A loading. Being 
highly hydrophobic, increase of cyclosporin A content up to 
such a high level seemed to result in significant alteration in 
the phase behavior of the system, which led to an increase 
in the particle size after self-nanoemulsifying. For F6, we 
observed much bigger particle size at all drug loading levels. 
This is due to the different phase behavior of other formula-
tions that have different compositions.
Based on these findings, we selected F4 with an 
oil:surfactant:cosurfactant ratio of 9:14:7 for further study of 
solid SNEDDS pellets. Each 1000 mg blank liquid SNEDDS 
contained 300 mg Labrafil M 1944 CS, 466.7 mg Cremophor 
EL, and 233.3 mg Transcutol P. This formulation was clear 
and able to self-nanoemulsify into a translucent nanoemul-
sion dispersion upon addition of water under gentle shaking. 
The particle size and zeta potential of the nanoemulsion 
dispersion was 21.2 ± 2.6 nm and −12.60 mV , respectively. 
The nanoemulsion dispersion showed no obvious changes 
in appearance after storage at ambient atmosphere for 
1 week.
Preparation and characterization  
of solid sNeDDs pellets
Because this was a new attempt to prepare solid SNEDDS 
by fluid-bed coating, several important issues concerning 
this technique should be clarified first, including the coating 
procedures and coating formulations.
In order to avoid use of an organic solvent, we used an 
aqueous dispersion of SNEDDS for coating. As observed 
in the liquid SNEDDS formulation, the aqueous dispersion 
of SNEDDS was in fact a dispersion of nanoemulsion. We 
hypothesized that the nanoemulsion dispersion could be 
reconcentrated and entrapped in the matrix of the coating layer 
after removal of water during the fluid-bed coating process. To 
entrap the liquid SNEDDS in the coating layer efficiently, it 
is very important to choose the appropriate coating materials. 
The coating materials should be flexible enough to form films 
after coating around non-pareil pellets. Although a series of 
polymers, such as hydroxypropyl celluloses, Eudragit® poly-
mers, and polyvinyl alcohol, are good film-forming materials, 
we selected polyvinylpyrrolidone in this study because of its 
instant dissolution ability and moderate viscosity at a rela-
tively high aqueous concentration.24 After the liquid SNEDDS 
was dispersed in water, polyvinylpyrrolidone K30 was added 
and completely dissolved. Therefore, the coating fluid was in 
fact a mixture of polyvinylpyrrolidone K30 aqueous solution 
and a dispersed nanoemulsion.
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Figure 1 A typical pseudoternary phase diagram with deionized water, Labrafil M® 1944 cs (oil) and cremophor® eL/Transcutol P® (surfactant/cosurfactant, Km = 2) as three 
vertices. The dark region indicates area of self-nanoemulsifying (infinite dilution), whereas the gray region indicates an area of nanoemulsion that turns into a milky emulsion 
upon dilution with water. The red line shows the dilution profile of the liquid SNEDDS (F4 in Table 1) for the solid SNEDDS pellets study. The blue point indicates the 
nanoemulsion dispersion of the liquid sNeDDs after dilution with water. The particle size was 21.2 nm as measured by Zetasizer Nano.
Abbreviation: sNeDDs, self-nanoemulsifying drug delivery system.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
800
Lei et al
T
a
b
l
e
 
1
 
F
o
r
m
u
l
a
t
i
o
n
 
d
e
t
a
i
l
s
 
f
o
r
 
l
i
q
u
i
d
 
s
N
e
D
D
s
F
o
r
m
u
l
a
t
i
o
n
 
c
o
d
e
O
i
l
S
u
r
f
a
c
t
a
n
t
s
C
o
s
u
r
f
a
c
t
a
n
t
s
O
i
l
:
S
A
K
m
S
o
l
u
b
i
l
i
t
y
 
o
f
 
 
C
y
A
 
(
m
g
/
g
)
P
a
r
t
i
c
l
e
 
s
i
z
e
 
b
y
 
i
n
t
e
n
s
i
t
y
 
w
e
i
g
h
t
i
n
g
 
(
n
m
)
B
l
a
n
k
6
%
 
C
y
A
8
%
 
C
y
A
1
0
%
 
C
y
A
1
2
%
 
C
y
A
F
1
L
a
b
r
a
fi
l
 
M
 
1
9
4
4
 
C
S
c
r
e
m
o
p
h
o
r
 
r
h
4
0
P
r
o
p
y
l
e
n
e
 
g
l
y
c
o
l
3
:
7
1
7
1
.
0
 
±
 
7
.
9
–
–
–
–
–
F
2
e
t
h
y
l
 
o
l
e
a
t
e
T
w
e
e
n
 
8
0
P
e
g
 
4
0
0
4
:
6
2
1
1
6
.
4
 
±
 
8
.
2
–
–
–
–
–
F
3
e
t
h
y
l
 
o
l
e
a
t
e
T
w
e
e
n
 
8
0
T
r
a
n
s
c
u
t
o
l
 
P
3
:
7
2
1
1
0
.
9
 
±
 
6
.
9
–
–
–
–
–
F
4
L
a
b
r
a
fi
l
 
M
 
1
9
4
4
 
C
S
c
r
e
m
o
p
h
o
r
 
e
L
T
r
a
n
s
c
u
t
o
l
 
P
3
:
7
2
1
7
2
.
4
 
±
 
7
.
3
2
1
.
1
 
±
 
2
.
8
2
1
.
0
 
±
 
2
.
8
2
1
.
2
 
±
 
2
.
6
2
1
.
8
 
±
 
2
.
7
1
3
.
4
 
±
 
1
.
2
 
(
3
.
9
7
%
)
*
3
5
.
6
 
±
 
4
.
8
 
(
1
1
.
0
2
%
)
*
2
8
1
.
9
 
±
 
3
4
.
4
 
(
8
5
.
0
0
%
)
*
F
5
L
a
b
r
a
fi
l
 
M
 
1
9
4
4
 
C
S
c
r
e
m
o
p
h
o
r
 
e
L
L
a
b
r
a
s
o
l
3
:
7
2
1
2
4
.
7
 
±
 
8
.
4
–
–
–
–
–
F
6
e
t
h
y
l
 
o
l
e
a
t
e
c
r
e
m
o
p
h
o
r
 
e
L
T
r
a
n
s
c
u
t
o
l
 
P
4
:
6
2
1
6
2
.
4
 
±
 
6
.
6
4
1
.
6
 
±
 
1
2
.
3
4
2
.
1
 
±
 
1
4
.
4
4
3
.
9
 
±
 
1
3
.
5
2
3
.
0
 
±
 
2
.
6
 
(
2
1
.
0
0
%
)
*
1
1
3
.
2
 
±
 
1
5
.
1
 
(
7
9
.
0
0
%
)
*
–
N
o
t
e
s
:
 
*
M
u
l
t
i
p
l
e
 
p
e
a
k
s
;
 
–
 
n
o
t
 
d
e
t
e
c
t
e
d
.
A
b
b
e
v
i
a
t
i
o
n
s
:
 
c
y
A
,
 
c
y
c
l
o
s
p
o
r
i
n
 
A
;
 
P
e
g
,
 
p
o
l
y
e
t
h
y
l
e
n
e
 
g
l
y
c
o
l
;
 
s
N
e
D
D
s
,
 
s
e
l
f
-
n
a
n
o
e
m
u
l
s
i
f
y
i
n
g
 
d
r
u
g
 
d
e
l
i
v
e
r
y
 
s
y
s
t
e
m
.
Coating of liquid SNEDDS went smoothly under the coat-
ing conditions in this study. Due to the good film-forming 
properties of polyvinylpyrrolidone K30 and the relative low 
viscosity of the bulk liquid, the coating process was made 
flexible to produce good quality pellets within a wide range 
of preparative conditions. To identify the capacity of fluid-
bed coating to hold liquid SNEDDS, we investigated the 
formulations containing different levels of liquid SNEDDS in 
the coating layer (0%–40%). Moreover, we also investigated 
the formulations containing different levels of cyclosporin A 
in the liquid SNEDDS (6%–8%) and the formulations with 
different CWG (100%–400%). Table 2 shows the formula-
tion details of the solid SNEDDS pellets investigated in this 
study. All batches of products could be obtained with a high 
yield of over 80%, except for the formulation containing 
50% liquid SNEDDS that produced only aggregates of pel-
lets due to the presence of too much liquid. Figure 2 shows 
that all batches of the solid SNEDDS pellets were white and 
spherical, and no trace of SNEDDS “oil” in the outer surface 
of the pellets could be observed visually. Figure 3 shows 
the scanning electron microscopic photographs of the solid 
SNEDDS pellets prepared under different conditions. When 
the liquid SNEDDS content was over 30% in the coating 
layer, the outer surface of the pellets was smooth. This could 
be attributed to the plasticizing effect of the liquid SNEDDS 
because oils, surfactants, and cosurfactants in the formulation 
can work as plasticizers.30 However, the surfaces of the final 
products were not smooth at all when the liquid SNEDDS 
level was lower than 20% because of the presence of less 
“plasticizer”. From the cross-sectional view of the pellets, 
the layer of solid SNEDDS was tightly packed and could be 
easily distinguished from the non-pareil cores.
However, the presence of non-pareil cores led to an 
enlarged volume of the dosage form as compared with the 
pellets prepared by extrusion/spheronization without use 
of non-pareil cores. One approach to overcome this prob-
lem is to increase the thickness of the coating layer. If the 
pellets were prepared at 100% CWG, the non-pareil cores 
would occupy 50% of the weight of the total formulation. 
If the CWG were increased to 400%, the non-pareil cores 
would occupy only 20% of the weight of the final product. 
Theoretically, solid SNEDDS pellets can be produced at any 
CWG as long as the coating is kept. However, a significant 
increase in CWG leads to significantly increased diameter 
and bulk weight of the pellets, resulting in a significant 
change in their aerodynamic conditions. Obvious disorder 
in the fluidized status could be observed visually from the 
observing window of the fluid-bed coater. Although a CWG International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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AB
CD
EF
GH
Figure 2 Optical photographs of the solid sNeDDs pellets, where the formulations 
are defined in Table 2. A−D) sF0–3 (liquid sNeDDs loading 0%, 20%, 30%, 40%); 
E, F) sF5, 6 (cWg 100%, 400%); G, H) sF7, 8 (cyclosporin A loading 6%, 10%).
Abbreviations:  sNeDDs,  self-nanoemulsifying  drug  delivery  system;  cWg, 
coating weight gain.
Table 2 Formulation details for solid sNeDDs pellets
Formulation 
code
Liquid SNEDDS 
loading in the 
coating layer (%)
Theoretical  
CWG (%)
CyA loading in 
the Liquid 
SNEDDS (%)
Coating gain  
of protective  
coating with 
PVP K30 (%)
Recovery (%) Friability (%)
sF0 / 200 / / 79.5 0.19
sF1 20 200 8 / 81.7 0.31
sF2 30 200 8 / 82.6 0.29
sF3 40 200 8 / 84.8 0.15
sF4 50 200 8 / – –
sF5 40 100 8 / 81.1 0.13
sF6 40 400 8 / 81.9 0.19
sF7 40 200 6 / 83.7 0.18
sF8 40 200 10 / 82.7 0.17
sF9 40 200 8 5 82.9 0.17
Note: – not detected; / not applicable; bold figures denote comparison in each column.
Abbreviations: cWg, coating weight gain; cyA, cyclosporin; PVP, polyvinylpyrrolidone; sNeDDs, self-nanoemulsifying drug delivery system.
of over 400% can possibly be achieved, we only investi-
gated systems with CWGs less than 400% because previous 
experience indicated that increasing CWGs to over 400% 
would result in significant change, even collapse, of the 
fluidizing state of the pellets, necessitating adjustment of 
the coating parameters.31 In this study, all batches of solid 
SNEDDS pellets were prepared with good appearance 
(Figures 2 and 3, and Table 2). In addition to increasing the 
CWG, the load of liquid SNEDDS in the coating layer can 
be further increased by screening appropriate adsorbents. 
However, we focused on the fundamental issues of this 
technique in this proof-of-concept study, and will leave the 
optimization work for future investigation.
It should be noted that we avoided using volatile cosur-
factants, such as ethanol, in the liquid SNEDDS formulation 
because any volatile solvents would be removed during the 
spraying/drying process, leading to significant change in the 
phase behavior of the liquid SNEDDS.
Although no obvious oozing of “oily” SNEDDS was 
observed visually on the surface of the pellets, even when the 
SNEDDS loading was as high as 40%, the solid SNEDDS 
pellets showed a tendency to stick to each other slightly 
after being stored at ambient temperature for about 2 weeks. 
Increasing the liquid SNEDDS content in the coating layer 
resulted in more severe sticking of the pellets. Therefore, we 
further coated the solid SNEDDS pellets with a protective 
layer of polyvinylpyrrolidone K30. The results showed that 
an outer layer of polyvinylpyrrolidone K30 at a 5% CWG 
level helped to improve the overall appearance and protect 
the pellets from aggregating, but did not enlarge the bulk 
volume of the products significantly.
reconstitution properties of solid 
sNeDDs pellets
The solid SNEDDS pellets (SF3 in Table 2) were read-
ily dispersed in deionized water. The resulting aqueous 
dispersion looked clear (slightly translucent), which was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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similar to the appearance of the liquid SNEDDS (F4 in 
Table 1). The particle size of the reconstituted nanoemul-
sions was 23.7 ± 2.9 nm, which was not significantly dif-
ferent (P . 0.05) from the particle size (21.2 ± 2.6 nm) of 
liquid SNEDDS (F4). The results indicate that solidification 
of liquid SNEDDS in polyvinylpyrrolidone K30 matrix in 
the coating layer did not lead to significant variation in the 
particle size of the nanoemulsion. The self-nanoemulsifying 
performance was well preserved in the solid SNEDDS 
pellets.
Powder X-ray diffraction analysis
A liquid SNEDDS (F4) has the capability to solubilize 
approximately 16% (w/w) cyclosporin A. To guarantee com-
plete solubilization of cyclosporin A in the formulation after 
coating, the drug loading was set at less than 10%. However, 
it is desirable to identify the physical state of cyclosporin A 
in solid SNEDDS formulations because the presence of solid 
polyvinylpyrrolidone might alter the solubilizing state of 
cyclosporin A. Figure 4 shows the powder X-ray diffraction 
curves of the crystalline cyclosporin A, physical mixture, and 
solid SNEDDS pellet powder. Figure 4 shows that crystalline 
cyclosporin A demonstrated typical diffraction peaks ranging 
from 2.5° to 45° (2θ), whereas polyvinylpyrrolidone K30, an 
amorphous polymer, did not show these typical diffraction 
peaks. The physical mixture showed diffraction peaks at a 
position similar to that of crystalline cyclosporin A, with a 
reduced intensity due to reduced concentration of crystalline 
cyclosporin A in the mixture. As expected, the solid SNEDDS 
samples did not show any sign of diffraction, indicating 
the nonexistence of cyclosporin A precipitate in the final 
products. We also used differential scanning calorimetry to 
identify crystalline cyclosporin A in the final products, which 
nevertheless failed due to the extremely low endotherm of 
crystalline cyclosporin A.32
redispersibility of solid sNeDDs pellets
When studying the redispersibility of the solid SNEDDS 
pellets, we assumed that cyclosporin A was associated with 
the reconstituted nanoemulsions after redispersing, and then 
monitored the content of cyclosporin A in the redispersing 
medium. Theoretically, surface-deposited cyclosporin A can 
A
A'
B
B'
C
C'
D
D'
E
E'
F
F'
G
G'
H
H'
Figure 3 Scanning electron microscopic photographs of the surface and cross-section view of solid SNEDDS pellets, where the formulations are defined in Table 2. Surface: 
A−D) sF1–3 (liquid sNeDDs loading 0%, 20%, 30%, 40%); E, F) sF5, 6 (cWg 100%, 400%); G, H) sF7, 8 (cyclosporin A loading 6%, 10%). cross-section: A′–D′) sF1−3; 
E′, F′) sF5, 6; G′, H′) sF7, 8.
Abbreviations: sNeDDs, self-nanoemulsifying drug delivery system; cWg, coating weight gain.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
803
self-nanoemulsifying cyclosporin A pellets
also contribute to the bulk redispersibility profile. However, 
this was unlikely to have happened in this study because we 
deliberately used deionized water as the redispersing medium 
in which the solubility of cyclosporin A was   negligible. 
The rapid redispersion profiles can only be attributed to 
nanoemulsion-associated cyclosporin A.
Solid SNEDDS pellets should retain the ability of liquid 
SNEDDS to redisperse quickly into nanoemulsion in aque-
ous medium. However, the redispersing of SNEDDS from 
solid pellets may be impeded because the compact coating 
layer takes time to dissolve. Figure 5 shows the redispers-
ing profiles in water of the solid SNEDDS pellets. Liquid 
SNEDDS rapidly dispersed into water, achieving near 90% 
and 100% redispersion at 5 and 10 minutes, respectively 
(Figure 5). All formulations of solid SNEDDS pellets showed 
a slower redispersing rate compared with those of the liquid 
SNEDDS. We investigated the effect of some variables on 
the redispersion rate, including liquid SNEDDS loading in 
the coating layer, cyclosporin A loading in liquid SNEDDS, 
CWG, and the outer protective coating. The loading of 
liquid SNEDDS and total CWG significantly affected the 
  redispersion rate, whereas the loading of cyclosporin A 
within the investigated range and outer protective coating 
did not show any significant influence.
The redispersion rate was slowest when the liquid 
SNEDDS was at the lowest loading level (20%), which 
achieved only 70% redispersion at 10 minutes and complete 
redispersion at 30 minutes. For formulations containing more 
liquid SNEDDS (30% and 40%), redispersion was faster, 
achieving approximately 85% redispersion at 10 minutes, but 
with a similar redispersion completion time of   30   minutes. 
The slower redispersion rate can be attributed to the fact that 
pellets have a smaller dissolution surface and thus a slower 
dissolution rate for the coating layer, as observed in our pre-
vious study of solid dispersion pellets.25 However, when the 
content of liquid SNEDDS in the coating layer was increased 
to 30%–40%, the redispersion rate was increased, which 
could be interpreted as being due to the readily dispersing 
nature of the liquid SNEDDS.
Increasing the total CWG to 400 times that of the non-
pareil cores significantly reduced the total redispersion 
rate. As shown in Figure 5B, the redispersion rate was only 
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60% at 10 minutes when CWG was 400%, and it took over 
45   minutes to complete the redispersion. This could be 
explained simply by the increased coating thickness and 
reduced dissolution surface. It took less than 20 minutes to 
complete the redispersion when CWG was below 200%. 
Although the pellets redispersed somewhat more slowly with 
100% CWG, there was no significant difference between the 
pellets with CWGs of 100% and 200%.
Cyclosporin A loading within the range of 6%–8% did not 
significantly change the redispersion profiles. Although pro-
tective coating with 5% polyvinylpyrrolidone K30 resulted 
in a slightly slower redispersion rate, there was no significant 
difference (P . 0.05) between protected and unprotected 
formulations. It is suggested that protective coating with 
blank polymers like polyvinylpyrrolidone K30 could be a 
potential approach to improving further the quality of solid 
SNEDDS pellets.
In general, in vitro characterization and redispersion stud-
ies confirmed that the fluid-bed coating could be used as a 
new technique to prepare solid SNEDDS pellets with good 
quality and recovery. However, there are still many aspects 
that need to be clarified. One of the concerns is physical 
stability upon storage. Special attention should be paid to 
studying the physical changes in the redispersibility and sur-
face properties (eg, oozing out of the liquid) under stress, and 
accelerated and long-term testing conditions. Another concern 
is the effect of solidification and presence of the polymer on 
self-nanoemulsifying ability and in vivo performance (eg, 
oral bioavailability). Therefore, we will focus on the effect of 
solidification on self-microemulsifying properties, stability, 
and oral bioavailability in the next stage of our research.
Conclusion
Solid SNEDDS pellets were successfully prepared by a 
fluid-bed coating technique with high efficiency. Up to 40% 
of liquid SNEDDS could be entrapped in the coating layer, 
with polyvinylpyrrolidone K30 as the film-forming   material. 
Visual observation and scanning electron microscopic 
analysis demonstrated good surface properties for the solid 
SNEDDS pellets. Total coating weight gain up to 400% 
could be achieved without interruption of the coating process. 
A redispersion study in water showed faster release at higher 
loading levels of liquid SNEDDS, whereas the increase in 
total coating weight significantly decreased the dispersion 
rate. This technique has considerable potential for use in the 
preparation of SNEDDS pellets.
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